Busca un médico

Ephraim E. Parent, M.D., Ph.D.

Publicaciones

  1. Savir-Baruch B, Parent E. Beyond the AJR: PET/MRI Using (68)Ga-RM2 Has Superior Performance to MRI Alone in the Localization of Lesions in Patients With Biochemical Failure After Prostate Cancer Treatment. AJR Am J Roentgenol. 2024 May 15 [Epub ahead of print]
    View PubMed
  2. Kase AM, Gleba J, Miller JL, Miller E, Petit J, Barrett MT, Zhou Y, Parent EE, Cai H, Knight JA, Orme J, Reynolds J, Durham WF, Metz TM, Meurice N, Edenfield B, Alasonyalilar Demirer A, Bilgili A, Hickman PG, Pawlush ML, Marlow L, Wickland DP, Tan W, Copland JA. Patient-derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for the management of metastatic castration-resistant prostate cancer. Mol Cancer Ther. 2024 Mar 6 Epub 2024 Mar 06
    View PubMed
  3. Bullock C, McCann M, Sharma A, Young JR, Metcalfe AM, Parent EE. FDG PET/CT and thyroid biopsy leads to neurosarcoidosis diagnosis. Radiol Case Rep. 2023 Nov; 18 (11):3932-3935 Epub 2023 Aug 28
    View PubMed
  4. Li KP, Gleba JJ, Parent EE, Knight JA, Copland JA 3rd, Cai H. Radiosynthesis and Preliminary Evaluation of [(11)C]SSI-4 for the Positron Emission Tomography Imaging of Stearoyl CoA Desaturase 1. Mol Pharm. 2023 Aug 7; 20 (8):4129-4137 Epub 2023 July 06
    View PubMed
  5. Orciuolo J, Sharma A, Parent EE, Accurso JM, Jain MK, Young JR. Incidental Airway Findings on PET/CT with (18)F-PSMA. J Nucl Med. 2023 Jun; 64 (6):993 Epub 2023 Jan 05
    View PubMed
  6. Gococo-Benore DA, Kuhlman J, Parent EE, Sharma A, Accurso J, Yang M, Kendi AT, Johnson G, Sonbol MB, Hobday T, Halfdanarson TR, Starr J. Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden. J Nucl Med. 2023 Jun; 64 (6):880-884 Epub 2023 Apr 20
    View PubMed
  7. Brahmbhatt P, Ataei F, Parent EE, Sharma A. Atypically Intense Pharmacologically Induced Brown Fat Activation on FDG PET/CT. Clin Nucl Med. 2023 Mar 1; 48 (3):233-236 Epub 2023 Jan 10
    View PubMed
  8. Parent EE, Fowler AM. Nuclear Receptor Imaging In Vivo-Clinical and Research Advances. J Endocr Soc. 2023 Jan 6; 7 (3):bvac197 Epub 2022 Dec 31
    View PubMed
  9. Davis J, Kimbrough EO, Alhaj Moustafa M, Jiang L, Gupta V, Parent E, Tun HW. Successful CNS-Centric Therapeutic Management and Genomic Profiling of Primary Cranial Vault Diffuse Large B-Cell Lymphoma. J Blood Med. 2023; 14:49-55 Epub 2023 Jan 22
    View PubMed
  10. Bilen MA, Akintayo A, Liu Y, Abiodun-Ojo O, Kucuk O, Carthon BC, Schuster DM, Parent EE. Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [(68)Ga]Ga DOTATATE PET-CT. Cancers (Basel). 2022 Dec 8; 14 (24) Epub 2022 Dec 08
    View PubMed
  11. Ataei F, Sharma A, Stanborough R, Parent EE. FDG PET-MRI evaluation of synchronous gallbladder adenocarcinoma and POEMS syndrome. Radiol Case Rep. 2022 Nov; 17 (11):4294-4298 Epub 2022 Sept 13
    View PubMed
  12. Parent EE, Kase AM. A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer. Cancers (Basel). 2022 Sep 1; 14 (17) Epub 2022 Sept 01
    View PubMed
  13. Parent EE, Savir-Baruch B, Gayed IW, Almaguel F, Chin BB, Pantel AR, Armstrong E, Morley A, Ippisch RC, Flavell RR. (177)Lu-PSMA Therapy. J Nucl Med Technol. 2022 Sep; 50 (3):205-212 Epub 2022 July 26
    View PubMed
  14. Parent EE, Savir-Baruch B, Gayed IW, Almaguel F, Chin B, Pantel AR, Armstrong E, Morley A, Ippisch RC, Flavell RR. JNMT continuing education: (177)Lu PSMA therapy. J Nucl Med Technol. 2022 Jul 26 Epub 2022 July 26
    View PubMed
  15. Kase AM, Tan W, Copland JA 3rd, Cai H, Parent EE, Madan RA. The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer. Cancers (Basel). 2022 Mar 8; 14 (6) Epub 2022 Mar 08
    View PubMed
  16. Parent EE, Sethi I, Nye J, Holder C, Olson JJ, Switchenko J, Tade F, Akin-Akintayo OO, Abiodun-Ojo OA, Akintayo A, Schuster DM. 82Rubidium chloride positron emission tomography discrimination of recurrent intracranial malignancy from radiation necrosis. Q J Nucl Med Mol Imaging. 2022 Mar; 66 (1):74-81 Epub 2019 Dec 09
    View PubMed
  17. Gococo-Benore DA, Parent E, Sharma A, Accurso J, Yang M, Kendi AT, Sonbol B, Halfdanarson TR, Starr JS. Hepatotoxicity from peptide receptor radionuclide therapy (prrt) in neuroendocrine tumors (nets) patients with very high liver tumor burden. Pancreas. 2022; 51(3):E47.
  18. Sharma A, Navaz AJ, Pandey MK, Parent EE. Unusual Increased Blood Pool Activity on 68Ga-DOTATATE PET/CT in a Patient With Metastatic Neuroendocrine Disease. Clin Nucl Med. 2022 Feb 1; 47 (2):137-139
    View PubMed
  19. Covington MF, Parent EE, Dibble EH, Rauch GM, Fowler AM. Advances and Future Directions in Molecular Breast Imaging. J Nucl Med. 2022 Jan; 63 (1):17-21 Epub 2021 Dec 09
    View PubMed
  20. Kase AM, Bullock C, Parrondo R, Alhaj Moustafa M, Iqbal M, Li KD, Parent EE, Tun H. Neuropsychiatric Manifestations of Lymphoma-Associated Cerebral Glucose Hypometabolism Can Be Reversed by Intensive Glucose Supplementation. Blood Lymphat Cancer. 2022; 12:17-21 Epub 2022 Mar 23
    View PubMed
  21. Kimbrough EO, Jiang L, Parent EE, Bourgeois K, Alhaj Moustafa M, Tun HW, Iqbal M. Primary Bone Marrow Lymphoma: De Novo and Transformed Subtypes. J Blood Med. 2022; 13:663-671. Epub 2022 Nov 14.
    View PubMed
  22. Advani P, Chumsri S, Pai T, Li Z, Sharma A, Parent E. Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients. Ann Nucl Med. 2021 Nov; 35 (11):1264-1269 Epub 2021 Aug 31
    View PubMed
  23. Parent EE, Johnson DR, Gleason T, Villanueva-Meyer JE. Neuro-Oncology Practice Clinical Debate: FDG PET to differentiate glioblastoma recurrence from treatment-related changes. Neurooncol Pract. 2021 Oct; 8 (5):518-525 Epub 2021 May 04
    View PubMed
  24. Kotecha R, Aboian M, Nabavizadeh SA, Parent EE, Trifiletti DM, Chao ST. Letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation. Neuro Oncol 2021 Aug 2; 23 (8):1408-1409
    View PubMed
  25. Pai TS, Rojas C, Wasserman MC, Parent EE, Cornell L, Chumsri S. Asymptomatic coronavirus disease 2019 mimicking metastatic breast cancer on positron emission tomography/computed tomography imaging. Radiol Case Rep. 2021 Aug; 16 (8):2226-2230 Epub 2021 June 13
    View PubMed
  26. Akintayo AA, Bilen MA, Abiodun-Ojo OA, Kucuk O, Carthon B, Chen Z, Jani AB, Parent EE, Schuster DM. Exploratory study of (18)F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancer. Am J Nucl Med Mol Imaging. 2021; 11 (3):218-229 Epub 2021 June 15
    View PubMed
  27. Parent EE, Patel D, Nye JA, Li Z, Olson JJ, Schuster DM, Goodman MM. [(18)F]-Fluciclovine PET discrimination of recurrent intracranial metastatic disease from radiation necrosis. EJNMMI Res. 2020 Dec 7; 10 (1):148 Epub 2020 Dec 07
    View PubMed
  28. Dudgeon MG, Sonavane SK, Parent EE, Khoor A, Thomas M. Co-existent Epicardial Paraganglioma and Anterior Mediastinal Thymoma. J Radiol Case Rep. 2020 Oct; 14 (10):16-30 Epub 2020 Oct 31
    View PubMed
  29. Bailey R, Sharma A, Parent EE. Carney-Stratakis Syndrome presenting as occult mediastinal paraganglioma. Radiol Case Rep. 2020 Sep; 15 (9):1528-1531 Epub 2020 July 04
    View PubMed
  30. Brugarolas P, Comstock J, Dick DW, Ellmer T, Engle JW, Lapi SE, Liang SH, Parent EE, Kishore Pillarsetty NV, Selivanova S, Sun X, Vavere A, Scott PJH, Society of Nuclear Medicine and Molecular Imaging Radiopharmaceutical Sciences Council. Fifty Years of Radiopharmaceuticals. J Nucl Med Technol. 2020 Jun; 48 (Suppl 1):34S-39S
    View PubMed
  31. Agely A, Sharma A, Parent EE, Nawaz A, Jain MK. Isolated Intravascular Prostate Carcinoma Recurrence Confirmed With 18F-Fluciclovine PET/CT and MRI. Clin Nucl Med. 2020 Jun; 45 (6):442-443
    View PubMed
  32. Nanni C, Zanoni L, Bach-Gansmo T, Minn H, Willoch F, Bogsrud TV, Edward EP, Savir-Baruch B, Teoh E, Ingram F, Fanti S, Schuster DM. [(18)F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0. Eur J Nucl Med Mol Imaging. 2019 Dec 11 [Epub ahead of print]
    View PubMed
  33. Parent E, Sharma A, Jain M. Amino Acid PET Imaging of Glioma Current Radiology Reports. April 2019; 7(5).
  34. Savir-Baruch B, Banks KP, McConathy JE, Molchanova-Cook OP, Parent EE, Takalkar A, Tulchinsky M, Yu JQ, Subramaniam RM, Schuster DM. ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer. Clin Nucl Med. 2018 Dec; 43 (12):909-917
    View PubMed
  35. Parent EE, Benayoun M, Ibeanu I, Olson JJ, Hadjipanayis CG, Brat DJ, Adhikarla V, Nye J, Schuster DM, Goodman MM. [(18)F]Fluciclovine PET discrimination between high- and low-grade gliomas. EJNMMI Res. 2018 Jul 25; 8 (1):67 Epub 2018 July 25
    View PubMed
  36. Parent EE, Schuster DM. Update on (18)F-Fluciclovine PET for Prostate Cancer Imaging. J Nucl Med. 2018 May; 59 (5):733-739 Epub 2018 Mar 09
    View PubMed
  37. Gauvain K, Ponisio MR, Barone A, Grimaldi M, Parent E, Leeds H, Goyal M, Rubin J, McConathy J. (18)F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors. Neurooncol Pract. 2018 Mar; 5 (1):28-36 Epub 2017 May 25
    View PubMed
  38. Fraum TJ, Fowler KJ, McConathy J, Parent EE, Dehdashti F, Grigsby PW, Siegel BA. PET/MRI for the body imager: abdominal and pelvic oncologic applications. Abdom Imaging. 2015 Aug; 40 (6):1387-404
    View PubMed
  39. Lee BC, Dence CS, Zhou H, Parent EE, Welch MJ, Katzenellenbogen JA. Fluorine-18 labeling and biodistribution studies on peroxisome proliferator-activated receptor-gamma ligands: potential positron emission tomography imaging agents. Nucl Med Biol. 2009 Feb; 36 (2):147-53
    View PubMed
  40. Parent EE, Dence CS, Sharp TL, Welch MJ, Katzenellenbogen JA. 7alpha-18F-fluoromethyl-dihydrotestosterone and 7alpha-18F-fluoromethyl-nortestosterone: ligands to determine the role of sex hormone-binding globulin for steroidal radiopharmaceuticals. J Nucl Med. 2008 Jun; 49 (6):987-94 Epub 2008 May 15
    View PubMed
  41. Fleming SA, Parent AA, Parent EE, Pincock JA, Renault L. Mechanistic analysis of the photocycloaddition of silyl-tethered alkenes. J Org Chem. 2007 Dec 7; 72 (25):9464-70 Epub 2007 Nov 13
    View PubMed
  42. Parent EE, Carlson KE, Katzenellenbogen JA. Synthesis of 7alpha-(fluoromethyl)dihydrotestosterone and 7alpha-(fluoromethyl)nortestosterone, structurally paired androgens designed to probe the role of sex hormone binding globulin in imaging androgen receptors in prostate tumors by positron emission tomography. J Org Chem. 2007 Jul 20; 72 (15):5546-54 Epub 2007 June 22
    View PubMed
  43. Parent EE, Dence CS, Jenks C, Sharp TL, Welch MJ, Katzenellenbogen JA. Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging. J Med Chem. 2007 Mar 8; 50 (5):1028-40
    View PubMed
  44. Parent EE, Jenks C, Sharp T, Welch MJ, Katzenellenbogen JA. Synthesis and biological evaluation of a nonsteroidal bromine-76-labeled androgen receptor ligand 3-[76Br]bromo-hydroxyflutamide. Nucl Med Biol. 2006 Aug; 33 (6):705-13 Epub 2006 July 21
    View PubMed
  45. Parent EE, Dence CS, Sharp TL, Welch MJ, Katzenellenbogen JA. Synthesis and biological evaluation of a fluorine-18-labeled nonsteroidal androgen receptor antagonist, N-(3-[18F]fluoro-4-nitronaphthyl)-cis-5-norbornene-endo-2,3-dicarboxylic imide. Nucl Med Biol. 2006 Jul; 33 (5):615-24
    View PubMed
  46. Bigott HM, Parent E, Luyt LG, Katzenellenbogen JA, Welch MJ. Design and synthesis of functionalized cyclopentadienyl tricarbonylmetal complexes for technetium-94m PET imaging of estrogen receptors. Bioconjug Chem. 2005 Mar-Apr; 16 (2):255-64
    View PubMed
  47. Fleming SA, Ward SC, Mao C, Parent EE. 2+2 Photocyclization Spectrum. 2002; 15(3):8-14.
PST-20445439